Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements
Search Results:
1-15 of 54820 results
Research shows flickering lights could be used in Alzheimer's treatment
By PBR Staff Writer
Researchers at the Massachusetts Institute of Technology (MIT) have discovered a non-invasive visual stimulation technique that can be potentially used for treating Alzheimer’s disease.
Aclaris starts phase 1 trial for ATI-50001 to treat alopecia totalis and alopecia universalis
Aclaris Therapeutics' investigational new drug (IND) application for ATI-50001, an orally administered investigational Janus Kinase (JAK) inhibitor, for the potential treatment of alopecia totalis and alopecia universalis has cleared the 30-day review period by the US Food and Drug Administration, allowing the company to go ahead with its planned Phase 1 clinical trial
Contract Research & Services > Clinical Trials > News
Sermonix signs licensing deal to further explore lasofoxifene for breast cancer treatment
Sermonix Pharmaceuticals has signed a licensing agreement to gain exclusive rights to Duke University intellectual property related to the use of lasofoxifene, its lead investigational drug, in the treatment of endocrine-resistant breast cancer.
Contract Research & Services > Contract Services > News
Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib
Cascadian Therapeutics announced that after a recent meeting with the US Food and Drug Administration (FDA) and discussions with the Company's external Steering Committee, it has amended the HER2CLIMB Phase 2 clinical trial of tucatinib (also known as ONT-380) by increasing the sample size so that, if successful, the trial could serve as a single pivotal study to support registration.
Production & Manufacturing > Process & Production > News
European Commission approves new indication for Novartis’ Lucentis eye drug
By PBR Staff Writer
The European Commission has approved the sixth indication for Novartis’ Lucentis, making it the only treatment available for a range of choroidal neovascularization (CNV) conditions.
Regulatory Affairs > News
Novartis' Zykadia beats chemotherapy in phase III lung cancer study
Novartis has unveiled Zykadia first-line study results demonstrating 16.6 month progression-free survival in patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
Genentech gets FDA approval for Avastin plus chemotherapy for specific type of advanced ovarian cancer
Genentech has secured approval from the US Food and Drug Administration (FDA) for Avastin (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, to treat patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
FDA grants fast track designation for Theravance's Velusetrag for idiopathic and diabetic gastroparesis
Theravance Biopharma has secured fast track designation from the US Food and Drug Administration (FDA) to velusetrag (TD-5108) for the treatment of symptoms associated with idiopathic and diabetic gastroparesis.
Production & Manufacturing > Process & Production > News
UK's CMA fines Pfizer and Flynn Pharma for epilepsy drug price hike
By PBR Staff Writer
Pfizer and Flynn Pharma have been fined a record amount for abusing their dominant position in the UK by charging excessive and unfair prices for an anti-epilepsy drug.
Production & Manufacturing > Manufacturing > News
AstraZeneca's Tagrisso reduces lung cancer progression by 70% in phase III study
By PBR Staff Writer
A phase 3 clinical trial assessing AstraZeneca's Tagrisso (osimertinib) for the second-line treatment of epidermal growth factor receptor (EGFR) T790M mutation-positive metastatic non-small cell lung cancer (NSCLC) demonstrated a significant treatment benefit.
Contract Research & Services > Clinical Trials > News
Purdue Pharma, AnaBios partner to advance research for non-opioid, non-NSAID compounds
Purdue Pharma and AnaBios have partnered to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain.
Contract Research & Services > Contract Services > News

PBR Supplier Recommendations

NSF Health Sciences Pharma Biotech
NSF partners with you to provide world-class regulatory and compliance consulting, auditing and training on a global basis.... Suppliers
Biovian - cGMP Contract Manufacturing of Biopharmaceuticals
Biovian is a dynamic and effective new generation one-stop-shop CMO in cGMP contract manufacturing of biopharmaceuticals. Biovian's services cover the full range from antigen isolation, expression, vector construction, cell line cultivation, cGMP protein purification to product fill and finish.... Suppliers
MSP Kofel – Analytical Accessories and Software Specialists
MSP Kofel provides analytical scientists with software and databases for interpretation, confirmation and archival of spectra, chromatographic data, structures and chemical compound information.... Suppliers
Sanofi CEPiA - Suppliers of APIs, Custom Synthesis and Pharmaceutical Contract Manufacturing
CEPiA (Commercial & External Partnership, Industrial Affairs) is an organization fully dedicated to third-party activities within the industrial affairs of Sanofi. ... Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Life Chemicals - Specialists in Development, Production and Sales of Novel Screen Compounds
Life Chemicals Inc, established in 2004, specialises in development, production and sales of novel screening compounds for HTS, targeted screening libraries and core building blocks for drug discovery projects.... Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
See more

PBR White Paper Recommendations

Biovian's Contract Manufacturing of Biopharmaceuticals By Biovian
Biovian is a one-stop-shop in GMP contract manufacturing of biopharmaceuticals covering services from early development to finished vial.... White Papers Going with the Flow: Malvern Instruments' Basic Introduction to Rheology By Malvern Instruments
Rheology concerns itself with materials that have aspects of both solids and liquids, and researches the flow and deformation of matter. Malvern Instruments explores this study, and reveals its fundamental in relation to force, deformation and time.... White Papers Malvern Instruments Shares its Buyer's Guide to Protein Stability Measurement Platforms By Malvern Instruments
As a leader in best practices during biopharmaceutical development, Malvern Instruments sheds light on effective protein stability analysis technologies for the biopharmaceutical industry.... White Papers Reliable, Long-range Wireless Sensors for Environmental Monitoring By Vaisala pbr
The Vaisala viewLinc Monitoring System tracks environmental conditions wirelessly using Vaisala’s VaiNet wireless devices based on LoRa™* technology. By using a chirp spread spectrum (CSS)* wireless protocol, VaiNet provides robust communication that is extremely reliable over long distances and under harsh, complex and obstructed conditions.... Contract Research & Services > Clinical Trials > White Papers Five Ways That the Mastersizer 3000 Saves you Money By Malvern Instruments
To earn its place in today’s busy analytical laboratories, an instrument must meet certain practical criteria, and stand-up to rigorous economic evaluation. For labs that need particle sizing, laser diffraction systems are typically the technology of choice; delivering accurate and reliable information for the broadest range of sample types. Here, we look at how the Mastersizer 3000, the market leading laboratory particle size analyzer from Malvern Instruments, can save you time, money and resources, and ultimately deliver a healthy return on investment.... White Papers See more
1-15 of 54820 results